IP Library Granted Patent US 8,216,819
Granted Patent B2
US 8,216,819 · App. 12/520,538 · Granted Jul 10, 2012

Generation of oncolytic adenoviruses and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,216,819
App. No.
12/520,538
Granted
Jul 10, 2012
Kind
B2
Abstract

The present invention relates to a method for the production of onolytic adenoviruses having increased potency and their therapeutic applications for cancer. Recombinant adenoviruses and methods to produce them are provided.

Claims (12)

1. An oncolytic isolated adenovirus which comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.

2. The adenovirus of claim 1 , wherein the adenovirus comprises SEQ ID NO:1.

3. The adenovirus of claim 2 , wherein the adenovirus comprises SEQ ID NO:2.

4. The adenovirus of claim 1 , further comprising a heterologous gene, wherein said heterologous gene is expressed within a cell infected with said adenovirus.

5. The adenovirus of claim 4 , wherein said heterologous gene is thymidine kinase.

6. The adenovirus of claim 4 , wherein said heterologous gene encodes a therapeutic protein selected from the group consisting of cytokines and chemokines, antibodies, factors known to induce cell death, pro-drug converting enzymes and immunoregulatory proteins.

7. The oncolytic adenovirus of claim 1 , further comprising a heterologous gene encoding an immunoregulatory protein.

8. A method of inhibiting growth of a cancer cell, comprising infecting said cancer cell with the oncolytic adenovirus of claim 1 .

9. The method of claim 8 , wherein said cancer cell is an ovarian cancer cell.

10. The method of claim 9 , wherein said cancer cell is a drug-resistant ovarian cancer cell.

11. The method of claim 8 , wherein the adenovirus comprises SEQ ID NO:1.

12. The method of claim 8 , wherein the adenovirus comprises SEQ ID NO:2.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2011
From: HYBRID BIOSYSTEMS LIMITED
To: PSIOXUS THERAPEUTICS LIMITED
Reel/Frame 026298/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2011
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: HYBRID BIOSYSTEMS LTD.
Reel/Frame 025830/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2009
From: HERMISTON, TERRY; KUHN, IRENE
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023496/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2009
From: HERMISTON, TERRY; KUHN, IRENE
To: BAYER SCHERING PHARMA AG
Reel/Frame 022857/0152 →